Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x100px
Organisation › Details

Complix (Group)

Complix is a biopharmaceutical company developing a pipeline of novel biotherapeutics, called Alphabodies™, for the treatment of cancer and autoimmune diseases. Alphabodies are a revolutionary class of protein therapeutics that have the potential to address a wide range of disease targets, in particular intracellular targets that are considered undruggable by current drug formats, such as antibodies or small chemicals. Complix´ current R&D efforts are focused on the development of Cell Penetrating Alphabodies (CPABs) that have demonstrated a unique capacity to enter tumor cells and tissues effectively and selectively modulate intracellular protein-to-protein interactions (PPIs), which play a key role in the initiation and progression of cancer. In December 2015 Complix signed a strategic collaboration with MSD, through a subsidiary, to develop novel Alphabody based therapeutics against two intracellular cancer targets. Complix is eligible to receive up to $280 million in upfront and development and regulatory milestones as well as tiered mid-single digit royalties on global sales revenues. Since its founding in 2008 Complix has raised a total of more than €27 million in venture financing. *


Period Start 2008-01-01 established
Products Industry biopharmaceutical
  Industry 2 Alphabody™ therapeutic (Alphabodies™)
Person Person Vaeck, Mark (Complix 201005– CEO before co-founder + founding CEO of ActoGenix + before Ablynx CEO)
Region Region Diepenbeek
  Country Belgium
  Street Agoralaan
BioVille, Building A-bis
  City 3590 Diepenbeek
    Address record changed: 2020-12-02
Basic data Employees n. a.
    * Document for »About Section«: Complix N.V.. (7/27/17). "Press Release: Complix Announces Expanded Strategic Oncology Collaboration with MSD to Develop Cell-Penetrating Alphabodies". Hasselt.
Record changed: 2024-02-12


Picture EBD Group Bio-Europe Spring 2024 Barcelona 650x200px

More documents for Complix (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Kenes Exhibitions Biomed Israel 2024 Tel Aviv 650x300px

» top